📊 BTAI Key Takeaways
Investment Thesis
BioXcel is in severe financial distress with negative stockholders' equity of -$88.9M, massive operating losses (-$40.2M), and severe cash burn (-$43.4M operating cash flow). The company is generating minimal revenue ($386K) while burning substantial cash, making near-term survival questionable without significant capital infusion.
BTAI Strengths
- Positive revenue growth of 64.2% YoY shows emerging product traction
- Cash position of $36.2M provides short-term runway for operations
- Current ratio of 1.17x indicates near-term liquidity is not immediately critical
BTAI Risks
- Negative stockholders' equity of -$88.9M indicates the company is technically insolvent on a balance sheet basis
- Operating cash burn of -$43.4M annually with only $36.2M cash suggests runway of less than one year without additional funding
- Extreme operating losses and net losses despite growth suggest business model is fundamentally unprofitable and may not achieve viability
- Long-term debt of $109.1M far exceeds total assets of $44.8M, creating unsustainable capital structure
- Minimal revenue base of $386K insufficient to service debt or fund operations at current burn rate
Key Metrics to Watch
- Quarterly revenue growth trajectory and path to profitability
- Cash runway and timing of next capital raise requirement
- Operating cash flow burn rate and working capital efficiency
BTAI Financial Metrics
💡 AI Analyst Insight
BioXcel Therapeutics, Inc. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
BTAI Profitability Ratios
BTAI vs Healthcare Sector
How BioXcel Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BTAI Balance Sheet & Liquidity
BTAI 5-Year Financial Trend
5-Year Trend Summary: BioXcel Therapeutics, Inc.'s revenue has grown significantly by 504% over the 5-year period, indicating strong business expansion. The most recent EPS of $-98.33 indicates the company is currently unprofitable.
BTAI Growth Metrics (YoY)
BTAI Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $98.0K | -$7.3M | $-2.18 |
| Q2 2025 | $120.0K | -$7.3M | $-2.45 |
| Q1 2025 | $168.0K | -$7.3M | $-1.50 |
| Q3 2024 | $214.0K | -$8.3M | $-0.32 |
| Q2 2024 | $457.0K | -$8.3M | $-0.21 |
| Q1 2024 | $206.0K | -$26.8M | $-0.87 |
| Q3 2023 | $137.0K | -$31.5M | $-1.49 |
| Q2 2023 | $457.0K | -$31.5M | $-1.35 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BTAI Capital Allocation
BTAI SEC Filings
Access official SEC EDGAR filings for BioXcel Therapeutics, Inc. (CIK: 0001720893)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BTAI
What is the AI rating for BTAI?
BioXcel Therapeutics, Inc. (BTAI) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BTAI's key strengths?
Positive revenue growth of 64.2% YoY shows emerging product traction. Cash position of $36.2M provides short-term runway for operations.
What are the risks of investing in BTAI?
Negative stockholders' equity of -$88.9M indicates the company is technically insolvent on a balance sheet basis. Operating cash burn of -$43.4M annually with only $36.2M cash suggests runway of less than one year without additional funding.
What is BTAI's revenue and growth?
BioXcel Therapeutics, Inc. reported revenue of $386.0K.
Does BTAI pay dividends?
BioXcel Therapeutics, Inc. does not currently pay dividends.
Where can I find BTAI SEC filings?
Official SEC filings for BioXcel Therapeutics, Inc. (CIK: 0001720893) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BTAI's EPS?
BioXcel Therapeutics, Inc. has a diluted EPS of $-6.38.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.